✨ Unlock Data Exports And Disclosure Access. Start Your 30-Day Free Trial Today →

Swedish Orphan Biovitrum AB (publ)

Common Name
Swedish Orphan Biovitrum
Country
Sweden
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,890
Ticker
SOBI
Exchange
NASDAQ STOCKHOLM AB
Description
Swedish Orphan Biovitrum AB (publ) is an international specialty biopharmaceutical company headquartered in Stockholm, Sweden, focused on developing and commercializing treatments for rare diseases in...

Swedish Orphan Biovitrum's Financial Statements Preview

Below are the financial statements of Swedish Orphan Biovitrum, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?
Learn More
All figures in millions of SEK
2024 as of 2024-12-31
2023 as of 2023-12-31
Assets
Non-current assets
Intangible assets
58,971a
59,580a
Tangible assets
1,584a
1,302a
Financial assets
166a
142a
Prepaid production costs
268a
0a
Deferred tax assets
1,293a
844a
Total non-current assets
62,282a
61,867a
Current assets
Inventories
4,159a
3,874a
Accounts receivable
5,195a
5,169a
Other receivables
405a
602a
Prepaid expenses and accrued income
2,262a
1,611a
Cash and cash equivalents
1,140a
904a
Total current assets
13,162a
12,160a
Total assets
75,444a
74,027a
Equity and liabilities
Equity
Share capital
195a
194a
Other contributed capital
17,186a
16,552a
Other reserves
981a
-934a
Retained earnings
18,039a
15,646a
Profit for the year
3,885a
2,409a
Equity attributable to parent company shareholders
40,286a
33,867a
Non-controlling interests
9a
0a
Total equity
40,295a
33,867a
Liabilities
Non-current liabilities
Borrowings
12,407a
11,356a
Deferred tax liabilities
6,702a
6,680a
Lease liabilities
268a
168a
Compensations post-employment benefits
276a
210a
Other provisions
52a
121a
Other liabilities
2,842a
2,530a
Total non-current liabilities
22,549a
21,065a
Current liabilities
Borrowings
3,926a
8,813a
Accounts payable
944a
1,024a
Tax liabilities
744a
74a
Lease liabilities
134a
148a
Other provisions
531a
535a
Other liabilities
646a
3,253a
Accrued expenses and deferred income
5,674a
5,248a
Total current liabilities
12,600a
19,095a
Total equity and liabilities
75,444a
74,027a
Limited Data Preview
You are viewing a limited preview of Swedish Orphan Biovitrum’s balance sheet data. The reported financial values are complete. The full dataset, available for download, additionally includes structured metadata for each line item, such as line item role (line item, subtotal, total) and financial classification (e.g., assets, liabilities, equity, revenue, expenses).
Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Download granular datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace all values back to their original sources
Formats Included
Excel
CSV
Json
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research

Verified Sources Behind Swedish Orphan Biovitrum’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Swedish Orphan Biovitrum’s data sources below and access millions more through our Disclosure Search.

a. Swedish Orphan Biovitrum's Annual Report 2024
Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?